[A case of scirrhous carcinoma of the stomach with malignant pleural and peritoneal carcinomatosis responding to the local administration of docetaxel (TXT)].
We report the case of a 34-year-old woman who underwent total gastrectomy for scirrhous carcinoma in the stomach (T4, N0, H0, CY1, P1, Stage IV). Despite adjuvant chemotherapy with TS-1 and/or CDDP, ascites caused by peritoneal carcinomatosis increased four months after gastrectomy. Therefore, intraperitoneal administration of docetaxel (TXT) at a dosage of 45 mg/m2 was applied. This therapy successfully maintained her good quality of life by inhibiting the increase of ascites without any severe adverse side effects for more than six months. When the left effusion from pleural carcinomatosis appeared nine months after the surgery, the intrathoracic administration of TXT succeeded in inhibiting the increase of pleural effusion over five months or more. In this case, intraperitoneal and intrapleural administrations of TXT were effective and temporarily improved the patient's quality of life without any side effects. We thought that the local administration of TXT was a useful treatment without severe toxicities for malignant pleural effusion and ascites in scirrhous carcinoma of the stomach.
Fujiki
Hiroshi
H
Dept. of Surgery, Akashi Municipal Hospital.
Kumano
Tatsuya
T
Yasuoka
Rie
R
Sonoyama
Yoshinobu
Y
Morita
Shuji
S
Mitsuo
Manabu
M
Oda
Toshihiko
T
Kadotani
Yoichi
Y
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy / Q000209:etiology; D000077143:Docetaxel; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D010538:Peritonitis / Q000188:drug therapy*; D010996:Pleural Effusion / Q000188:drug therapy / Q000209:etiology; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage*; D035423:Thoracic Cavity
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel